EP2019590A4 - Procédés pour traiter des maladies impliquant des troubles et des conditions associés au stress - Google Patents

Procédés pour traiter des maladies impliquant des troubles et des conditions associés au stress

Info

Publication number
EP2019590A4
EP2019590A4 EP07776752A EP07776752A EP2019590A4 EP 2019590 A4 EP2019590 A4 EP 2019590A4 EP 07776752 A EP07776752 A EP 07776752A EP 07776752 A EP07776752 A EP 07776752A EP 2019590 A4 EP2019590 A4 EP 2019590A4
Authority
EP
European Patent Office
Prior art keywords
conditions
methods
diseases
involving stress
related diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07776752A
Other languages
German (de)
English (en)
Other versions
EP2019590A1 (fr
Inventor
Peter J Obrien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therakos Inc
Original Assignee
Therakos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therakos Inc filed Critical Therakos Inc
Publication of EP2019590A1 publication Critical patent/EP2019590A1/fr
Publication of EP2019590A4 publication Critical patent/EP2019590A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0066—Psoralene-activated UV-A photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens or fucocoumarins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP07776752A 2006-05-03 2007-05-03 Procédés pour traiter des maladies impliquant des troubles et des conditions associés au stress Withdrawn EP2019590A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79747106P 2006-05-03 2006-05-03
PCT/US2007/010858 WO2007142769A1 (fr) 2006-05-03 2007-05-03 Procédés pour traiter des maladies impliquant des troubles et des conditions associés au stress

Publications (2)

Publication Number Publication Date
EP2019590A1 EP2019590A1 (fr) 2009-02-04
EP2019590A4 true EP2019590A4 (fr) 2011-08-03

Family

ID=38801786

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07776752A Withdrawn EP2019590A4 (fr) 2006-05-03 2007-05-03 Procédés pour traiter des maladies impliquant des troubles et des conditions associés au stress

Country Status (7)

Country Link
EP (1) EP2019590A4 (fr)
JP (1) JP2009535412A (fr)
CN (1) CN101484008A (fr)
BR (1) BRPI0709763A2 (fr)
CA (1) CA2651542A1 (fr)
MX (1) MX2008014111A (fr)
WO (1) WO2007142769A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2198873A1 (fr) * 2008-12-18 2010-06-23 Aposcience AG Préparation pharmaceutique renfermant le surnageant de cultures de cellules mononucléaires sanguines
EP2201954A1 (fr) * 2008-12-18 2010-06-30 Aposcience AG Préparation pharmaceutique
CN102242150A (zh) * 2011-05-11 2011-11-16 浙江大学 Hsp-gp96重组腺病毒载体及构建和应用
CN107485795A (zh) * 2017-09-18 2017-12-19 袁心洲 一种定向转移生物信息能量的系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5984887A (en) * 1996-03-29 1999-11-16 Therakos, Inc. Photopheresis treatment of leukocytes
US20030139466A1 (en) * 2001-11-29 2003-07-24 Peritt David L. Methods for pretreating a subject with extracorporeal photopheresis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482945A (en) * 1992-12-22 1996-01-09 American Home Products Corporation Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements
US20040185041A1 (en) * 2003-03-17 2004-09-23 Henna Vation, Llc Method for extracorporeal treatment of blood
US20050186600A1 (en) * 2004-01-13 2005-08-25 Osnat Sella-Tavor Polynucleotides encoding novel UbcH10 polypeptides and kits and methods using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5984887A (en) * 1996-03-29 1999-11-16 Therakos, Inc. Photopheresis treatment of leukocytes
US20030139466A1 (en) * 2001-11-29 2003-07-24 Peritt David L. Methods for pretreating a subject with extracorporeal photopheresis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2007142769A1 *

Also Published As

Publication number Publication date
MX2008014111A (es) 2009-03-06
WO2007142769A1 (fr) 2007-12-13
EP2019590A1 (fr) 2009-02-04
CA2651542A1 (fr) 2007-12-13
JP2009535412A (ja) 2009-10-01
BRPI0709763A2 (pt) 2011-10-04
CN101484008A (zh) 2009-07-15

Similar Documents

Publication Publication Date Title
IL291175A (en) Compositions and methods for treating collagen-mediated diseases
EP2032131A4 (fr) Procédé de traitement
EP2086023A4 (fr) Structure connectee et son procede de fabrication
GB2434521B (en) Plant treatment method and means therefor
IL195400A0 (en) Aldh-2 inhibitors in the treatment of addiction
EP2083862A4 (fr) Compositions et procédés pour traiter des maladies et des troubles oculaires
EP2170311A4 (fr) Compositions et procédés pour traiter ou empêcher des maladies auto-immunes
HK1162366A1 (en) Devices and methods for treating and or preventing diseases
IL204728A0 (en) Methods and compounds for treating retinol-related diseases
GB0610746D0 (en) Method of treatment
EP2056849A4 (fr) PROCÉDÉS ET COMPOSITIONS DE TRAITEMENT DE MALADIES MÉDIÉES PAR l'IGE
EP2049899A4 (fr) Méthodes de prévention et de traitement de maladies
GB0718918D0 (en) Compositions and methods for treating skin conditions
HK1129596A1 (en) Methods and compositions for treating disease
ZA200808076B (en) Methods for preventing and treating amyloidogenic diseases
EP2088862A4 (fr) Méthode de traitement du cancer
EP2019590A4 (fr) Procédés pour traiter des maladies impliquant des troubles et des conditions associés au stress
EP2064476A4 (fr) Système de tubes et son procédé de fabrication
EP2004219A4 (fr) Reactifs et procedes destines au traitement et a la prevention du cancer
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
EP1993564A4 (fr) Méthode et composition de traitement des maladies allergiques
EP2123172A4 (fr) Procédé de prévention de maladies chez des porcelets en période de sevrage
GB0607153D0 (en) Therapeutic Method
EP2002840A4 (fr) Procede de traitement de maladies cancereuses
EP2051522A4 (fr) Système et procédé de programmation d'enregistrement de programme de diffusion

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081203

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20110701

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 43/00 20060101ALI20110627BHEP

Ipc: A61K 41/00 20060101ALI20110627BHEP

Ipc: A01N 43/42 20060101AFI20110627BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120131

DAX Request for extension of the european patent (deleted)